An observational study of patients being treated for acute COVID-19 in a multicenter health care system observed virologic rebound in about 20 percent of patients treated with nirmatrelvir-ritonavir (N-R) versus about 2 percent of those who did not receive treatment. The findings are published in Annals of Internal Medicine.
Drug pricing experts skeptical that Florida’s drug import plan will work
The FDA authorized a program that would allow Florida to import cheaper drugs from Canada, though drug pricing experts say the plan is unlikely to
January 6, 2024